ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,360.79
0.26%
US Tech 100
18,566.00
0.26%
Dow Jones
38,868.04
0.18%
Brent Oil
81.195
-0.71%
Bitcoin
67,987.99
-2.19%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ChromaDex Corporation (CDXC)

  7. ChromaDex Corporation (CDXC) News

CDXC

ChromaDex (CDXC)

ChromaDex Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CDXC
DateTimeSourceHeadlineSymbolCompany
06/07/20248:34AMBusiness WireChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)NASDAQ:CDXCChromaDex Corporation
06/04/20248:32AMBusiness WireChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024NASDAQ:CDXCChromaDex Corporation
05/23/20248:34AMBusiness WireChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024NASDAQ:CDXCChromaDex Corporation
05/22/20248:32AMBusiness WireChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year AwardNASDAQ:CDXCChromaDex Corporation
05/08/20244:04PMBusiness WireChromaDex Corporation Reports First Quarter 2024 Financial ResultsNASDAQ:CDXCChromaDex Corporation
05/08/20244:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CDXCChromaDex Corporation
05/08/20244:01PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CDXCChromaDex Corporation
04/30/20248:32AMBusiness WireChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy SupplementNASDAQ:CDXCChromaDex Corporation
04/25/20248:34AMBusiness WireChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®NASDAQ:CDXCChromaDex Corporation
04/24/20248:34AMBusiness WireChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024NASDAQ:CDXCChromaDex Corporation
04/23/20248:32AMBusiness WireChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers MarketNASDAQ:CDXCChromaDex Corporation
03/26/20248:32AMBusiness WireChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency ProgramNASDAQ:CDXCChromaDex Corporation
03/06/20244:04PMBusiness WireChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 ResultsNASDAQ:CDXCChromaDex Corporation
03/06/20244:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CDXCChromaDex Corporation
03/06/20244:01PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:CDXCChromaDex Corporation
02/23/20249:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CDXCChromaDex Corporation
02/23/20248:59PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CDXCChromaDex Corporation
02/21/20248:32AMBusiness WireChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024NASDAQ:CDXCChromaDex Corporation
02/05/20248:32AMBusiness WireChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024NASDAQ:CDXCChromaDex Corporation
01/26/20244:08PMBusiness WireChromaDex to Present at the Lytham Partners 2024 Investor Select ConferenceNASDAQ:CDXCChromaDex Corporation
12/20/20239:04AMBusiness WireChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®NASDAQ:CDXCChromaDex Corporation
12/13/20234:00PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CDXCChromaDex Corporation
12/12/202310:30AMPR Newswire (US)Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+NASDAQ:CDXCChromaDex Corporation
12/04/20234:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CDXCChromaDex Corporation
11/30/20238:34AMBusiness WireA Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)NASDAQ:CDXCChromaDex Corporation
11/15/20238:32AMBusiness WireNewly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) PatientsNASDAQ:CDXCChromaDex Corporation
11/09/20238:32AMBusiness WireChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, November 14, 2023NASDAQ:CDXCChromaDex Corporation
11/08/20234:02PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:CDXCChromaDex Corporation
11/08/20234:02PMBusiness WireChromaDex Corporation Reports Third Quarter 2023 Financial ResultsNASDAQ:CDXCChromaDex Corporation
11/08/20234:01PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CDXCChromaDex Corporation
 Showing the most relevant articles for your search:NASDAQ:CDXC

Your Recent History

BIT
P12AF7
BNP PARIBAS ISSUANCE
BIT
S27006
Societe Generale Effekten
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved